tpi-1020

TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It acts as a prodrug that releases both the corticosteroid budesonide and nitric oxide, combining anti-inflammatory effects with bronchodilatory activity. The drug was developed for respiratory indications such as asthma and chronic obstructive pulmonary disease (COPD), aiming to provide enhanced bronchodilation and prolonged duration of action when combined with beta(2)-adrenoceptor agonists like salbutamol[1][2][5]. Its mechanism involves inhibition of histamine-induced bronchoconstriction through cGMP-dependent pathways mediated by released NO, in addition to the classic anti-inflammatory effects of corticosteroids[1].